BBOT BridgeBio Oncology Therapeutics Inc Forecast, Technical & Fundamental Analysis
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes... Show more
BBOT is expected to report earnings to fall 1.16% to -51 cents per share on September 02
Q2'26
Est.
$-0.52
Q1'26
Missed
by $0.06
Q4'25
Missed
by $0.07
The last earnings report on May 12 showed earnings per share of -52 cents, missing the estimate of -46 cents. With 238.55K shares outstanding, the current market capitalization sits at 683.07M.
A.I.dvisor tells us that BBOT and VKTX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BBOT and VKTX's prices will move in lockstep.
BBOT in +9.65% Uptrend, advancing for three consecutive days on July 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BBOT advanced for three days, in of 58 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 01, 2026. You may want to consider a long position or call options on BBOT as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BBOT just turned positive on June 25, 2026. Looking at past instances where BBOT's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .
BBOT moved above its 50-day moving average on July 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BBOT crossed bullishly above the 50-day moving average on July 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 52 cases where BBOT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BBOT moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 23 cases where BBOT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBOT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BBOT broke above its upper Bollinger Band on July 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.835) is normal, around the industry mean (22.746). P/E Ratio (0.000) is within average values for comparable stocks, (37.261). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.488). BBOT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (432.117).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
